Skip to main content
SpringerLink
Log in

Atorvastatin Improves Endothelial Function and Cardiac Performance in Patients with Dilated Cardiomyopathy: The Role of Inflammation

  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Aim

Statins have been demonstrated to significantly affect the prognosis and outcome of patients with cardiac diseases. Several studies have suggested pleiotropic effects of the statins in these patients. The present study was designed to examine the effects of atorvastatin on inflammation, endothelial function, cardiac performance and exercise tolerance in patients with idiopathic dilated cardiomyopathy (IDCM).

Methods

Sixty-four patients with IDCM were divided randomly into an atorvastatin treatment group (atorvastatin 10 mg/d orally) and a placebo control group. Before and 12 weeks after the treatment, circulating soluble intercellular adhesion molecule-1 (sICAM-1), Von Willebrand factor (vWF) and C-reactive protein (CRP) levels were detected using enzyme-linked immunosorbent assay (ELISA); Flow-mediated dilatation (FMD) of the brachial artery was measured, and left ventricular ejection fraction (LVEF) and the 6-min walk test (6MWT) evaluated.

Results

After atorvastatin treatment, LVEF increased from 34.5 ± 5.7% to 41.4 ± 4.5% (P < 0.05), and from 32.8 ± 4.0% to 36.9 ± 5.2% (P < 0.05) in the placebo group. Also, the distances covered in the 6MWT increased from 358 ± 61 m to 431 ± 66 m in the atorvastatin group, and from 351 ± 70 m to 382 ± 74 m in the placebo group (both p < 0.05 vs. baseline). The increases in LVEF and 6MWT distances were significantly greater in the atorvastatin than in the placebo group. sICAM-1, CRP and vWF levels decreased and FMD increased significantly in the atorvastatin group, but not in the control group. Correlation analysis showed that the baseline sICAM-1 level was positively correlated with plasma CRP and vWF levels (r = 0.554 and 0.628, respectively); FMD was inversely correlated with serum sICAM-1 and plasma vWF levels (r = −0.579 and −0.590, respectively) and positively correlated with LVEF and distance attained in 6MWT (r = 0.536 and 0.522, respectively).

Conclusions

Twelve weeks of treatment with atorvastatin significantly decreased serum sICAM-1, CRP and vWF levels, and improved the FMD, LVEF and 6MWT outcomes. Inhibition of inflammation, alleviating endothelium damage and endothelial dysfunction might comprise part of the underlying mechanisms leading to the improvement of LV function and exercise tolerance in patients with IDCM.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Celis R, Torre-Martinez G, Torre-Amione G. Evidence for activation of immune system in heart failure: is there a role for anti-inflammatory therapy? Curr Opin Cardiol. 2008;23:254–60.

    Article  PubMed  Google Scholar 

  2. Dahl CP, Gullestad L, Fevang B, Holm AM, Landro L, Vinge LE, et al. Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure. Eur J Heart Fail. 2008;10:352–9.

    Article  CAS  PubMed  Google Scholar 

  3. Sola S, Mir MQ, Lerakis S, Tandon N, Khan BV. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol. 2006;47:332–7.

    Article  CAS  PubMed  Google Scholar 

  4. Strey CH, Young JM, Lainchbury JH, Frampton CM, Nicholls MG, Richards AM, et al. Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure. Heart. 2006;92:1603–9.

    Article  CAS  PubMed  Google Scholar 

  5. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the treating to new targets (TNT) study. Circulation. 2007;115:576–83.

    Article  CAS  PubMed  Google Scholar 

  6. Kjekshus J, Apetrei E, Barrios V, Bohm M, Cleland JG, Cornel JH, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–61.

    Article  CAS  PubMed  Google Scholar 

  7. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:1231–9.

    Article  PubMed  Google Scholar 

  8. Kovacs I, Toth J, Tarjan J, Koller A. Correlation of flow mediated dilation with inflammatory markers in patients with impaired cardiac function. Beneficial effects of inhibition of ACE. Eur J Heart Fail. 2006;8:451–9.

    Article  CAS  PubMed  Google Scholar 

  9. Videm V, Albrigtsen M. Soluble ICAM-1 and VCAM-1 as markers of endothelial activation. Scand J Immunol. 2008;67:523–31.

    Article  CAS  PubMed  Google Scholar 

  10. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39:257–65.

    Article  PubMed  Google Scholar 

  11. Hesse B, Lindhardt TB, Acampa W, Anagnostopoulos C, Ballinger J, Bax JJ, et al. EANM/ESC guidelines for radionuclide imaging of cardiac function. Eur J Nucl Med Mol Imaging. 2008;35:851–85.

    Article  CAS  PubMed  Google Scholar 

  12. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7.

    Google Scholar 

  13. Jonsdottir S, Andersen KK, Sigurosson AF, Sigurosson SB. The effect of physical training in chronic heart failure. Eur J Heart Fail. 2006;8:97–101.

    Article  PubMed  Google Scholar 

  14. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN, et al. The prognostic value of circulating soluble cell adhesion molecules in patients with chronic congestive heart failure. Eur J Heart Fail. 2003;5:507–16.

    Article  CAS  PubMed  Google Scholar 

  15. Cugno M, Mari D, Meroni PL, Gronda E, Vicari F, Frigerio M, et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br J Haematol. 2004;126:85–92.

    Article  CAS  PubMed  Google Scholar 

  16. Fischer D, Rossa S, Landmesser U, Spiekermann S, Engberding N, Hornig B, et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur Heart J. 2005;26:65–9.

    Article  CAS  PubMed  Google Scholar 

  17. Bauersachs J, Hiss K, Fraccarollo D, Laufs U, Ruetten H. Simvastatin improves left ventricular function after myocardial infarction in hypercholesterolemic rabbits by anti-inflammatory effects. Cardiovasc Res. 2006;72:438–46.

    Article  CAS  PubMed  Google Scholar 

  18. Takemoto M, Node K, Nakagami H, Liao Y, Grimm M, Takemoto Y, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest. 2001;108:1429–37.

    CAS  PubMed  Google Scholar 

  19. Mulder DJ, van Haelst PL, Wobbes MH, Gans RO, Zijlstra F, May JF, et al. The effect of aggressive versus conventional lipid-lowering therapy on markers of inflammatory and oxidative stress. Cardiovasc Drugs Ther. 2007;21:91–7.

    Article  CAS  PubMed  Google Scholar 

  20. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711–9.

    Article  CAS  PubMed  Google Scholar 

  21. Nachtigal P, Pospisilova N, Jamborova G, Pospechova K, Solichova D, Andrys C, et al. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice. Life Sci. 2008;82:708–17.

    Article  CAS  PubMed  Google Scholar 

  22. Graciano AL, Bryant DD, White DJ, Horton J, Bowles NE, Giroir BP. Targeted disruption of ICAM-1, P-selectin genes improves cardiac function and survival in TNF-alpha transgenic mice. Am J Physiol Heart Circ Physiol. 2001;280:H1464–71.

    CAS  PubMed  Google Scholar 

  23. Wojnicz R, Wilczek K, Nowalany-Kozielska E, Szygula-Jurkiewicz B, Nowak J, Polonski L, et al. Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol. 2006;97:899–904.

    Article  CAS  PubMed  Google Scholar 

  24. Node K, Fujita M, Kitakaze M, Hori M, Liao JK. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation. 2003;108:839–43.

    Article  CAS  PubMed  Google Scholar 

  25. Lee R, Chan YH, Wong J, Lau D, Ng K. The 6-minute walk test predicts clinical outcome in Asian patients with chronic congestive heart failure on contemporary medical therapy: a study of the multiracial population in Singapore. Int J Cardiol. 2007;119:168–75.

    Article  PubMed  Google Scholar 

  26. Jordan AJ, Anguita MP. Effect of statin treatment on mortality in a large cohort of heart failure patients. Rev Esp Cardiol. 2009;62:323–7.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of paediatrics, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan, 430022, China

    Miao Liu, Fang Wang, Yanrong Wang & Runming Jin

Authors
  1. Miao Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fang Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanrong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Runming Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Runming Jin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, M., Wang, F., Wang, Y. et al. Atorvastatin Improves Endothelial Function and Cardiac Performance in Patients with Dilated Cardiomyopathy: The Role of Inflammation. Cardiovasc Drugs Ther 23, 369–376 (2009). https://doi.org/10.1007/s10557-009-6186-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-009-6186-3

Key words

Search

Navigation